Amentum Holdings (AMTM) Soars on ‘Nuclear Monopoly’ Hype as UBS Starts Coverage at Neutral

November 19, 2025

Amentum Holdings, Inc. (NYSE: AMTM) staged a powerful rally on Wednesday, with the stock jumping around 13–14% to about $24.7 by the close, after a burst of bullish commentary on its role in U.S. nuclear infrastructure coincided with fresh Wall Street coverage from UBS. ^[1]

The move caps a busy news day for the Chantilly‑based engineering and technology group, which now sits at the intersection of three big stories investors care about: nuclear energy expansion, defense contract wins, and a fast‑filling analyst coverage slate.

AMTM stock: double‑digit pop on heavy volume

According to real‑time and end‑of‑day data, Amentum shares traded between roughly $21.5 and $24.7 on November 19, 2025, closing near the high of the day at $24.74, up about 13.5%, on volume close to 5 million shares – well above recent daily levels. ^[2]

Pre‑market screens already showed AMTM up more than 8% as traders reacted to early commentary; the gains built through the session as Citron Research’s bullish thesis circulated across financial media and social platforms. ^[3]

For context, Amentum’s 52‑week trading range runs roughly $16–$27, meaning Wednesday’s spike has pushed the stock back toward the upper end of its recent band. ^[4]

Citron: “Nuclear monopoly” at the heart of a multi‑trillion opportunity

The biggest narrative driver today came from Citron Research, which flipped to a loudly bullish stance on Amentum. In posts and media summaries, Citron characterizes Amentum as effectively a “nuclear monopoly” inside the U.S. Department of Energy (DOE) ecosystem:

Citron asserts that Amentum helps manage roughly 90% of the DOE’s nuclear infrastructure, including complex weapons, cleanup and waste sites. ^[5]
The firm pegs a $55 share‑price target for AMTM – more than double Wednesday’s close – arguing that the market is not fully pricing the company’s “near‑monopoly” status and long‑duration contracts. ^[6]
Citron’s thesis is explicitly tied to U.S. nuclear policy, pointing to expectations of expanded DOE loan programs and aggressive capacity targets that could translate into hundreds of gigawatts of new nuclear capacity and hundreds of billions in spending over coming decades. ^[7]

Coverage of the note across outlets like Investing.com, Asianet Newsable, GuruFocus and Stocktwits amplified the message, with some calling out “extremely high” social‑media message volume and strongly bullish retail sentimentas the stock ripped higher. ^[8]

GuruFocus summarized the move as an 8.3% intraday jump following Citron’s call, reiterating the view that Amentum controls “over 90%” of U.S. nuclear infrastructure and highlighting the upside potential implied by the $55 target. ^[9]

UBS initiates coverage at Neutral with a $25 price target

Before the Citron buzz hit full speed, UBS initiated coverage on Amentum with a Neutral rating and a $25 price target – a shade above where the stock was trading before today’s spike and slightly below the closing price after the rally. ^[10]

Key points from UBS and follow‑on summaries:

UBS views Amentum as the product of a recent merger of two mid‑sized government services/IT businesses, creating a larger‑scale engineering and technology player serving defense, energy, space and intelligence missions. ^[11]
The bank highlights rapid top‑line expansion – roughly 50%+ revenue growth tied to the combination – with annual revenue around $12.7 billion. ^[12]
UBS points to differentiated drivers, including:
- space infrastructure,
- nuclear lifecycle work,
- and a relatively higher mix of commercial and international contracts versus typical U.S. government contractors. ^[13]
On the cautious side, UBS forecasts FY2026 and FY2027 revenue below current consensus, and warns of “limited near‑term re‑rate potential,” framing the Neutral stance as a balance between structural growth and valuation / execution risk. ^[14]

TipRanks, which tracks broker moves, echoed the theme: UBS’s Hold/Neutral rating joins an existing mix of Hold and Overweight opinions, with RBC Capital reiterating a Hold and $26 price target earlier this month, and Cantor Fitzgerald upgrading Amentum to Overweight in September with a $35 target. ^[15]

JPMorgan, meanwhile, initiated AMTM at Neutral with a $30 target in October, noting attractive strategic positioning but “limited growth prospects” relative to current expectations. ^[16]

Taken together, the broker community currently skews cautiously constructive: an average rating around Overweight/Hold territory and a consensus price target in the high‑$20s, now only modestly above today’s post‑rally levels. ^[17]

Defense and nuclear wins: MQ‑9 Reaper and Sellafield deals

Today’s excitement doesn’t exist in a vacuum. Amentum has been stacking high‑profile defense and nuclear contractsthrough the back half of 2025.

U.S. Air Force MQ‑9 Reaper contract

On November 12, 2025, Amentum announced it had been awarded the Remotely Piloted Aircraft Maintenance Support IDIQ contract by the U.S. Air Force Air Combat Command, with a ceiling value of up to $995 million over five years. ^[18]

Under the deal, Amentum will:

provide maintenance and sustainment support for the MQ‑9 Reaper unmanned aerial system;
deploy specialized personnel, weapons‑loading support and ground equipment across U.S. and overseas sites;
and help ensure the aircraft remain combat‑ready for training and operational missions. ^[19]

Simply Wall St, in a piece published today, argued that the MQ‑9 contract strengthens Amentum’s near‑term investment narrative, but also cautioned that profitability is still relatively new, earnings look expensive versus peers and execution risk remains, given a comparatively inexperienced board and management team. ^[20]

UK Sellafield nuclear decommissioning framework

On October 31, 2025, Amentum also revealed it had secured prime positions on a multi‑billion‑pound framework to deliver decommissioning services at the Sellafield nuclear site in the UK, one of the most complex nuclear cleanup projects in the world. ^[21]

The Sellafield framework further tightens Amentum’s association with specialized nuclear lifecycle work, ranging from operations and maintenance to long‑term decommissioning and waste management.

A long nuclear pedigree

Beyond the new deals, Amentum’s own materials emphasize its long‑standing role in nuclear security and deterrence, including support for U.S. and allied nuclear assets and work at facilities such as Lawrence Livermore National Laboratory and Idaho National Laboratory. ^[22]

The company describes itself as a global leader in advanced engineering and innovative technology solutions, headquartered in Chantilly, Virginia, with more than 53,000 employees across roughly 80 countries. ^[23]

Financial profile: big revenue, thin margins and notable leverage

The bullish narrative around nuclear dominance sits against a financial backdrop that is strong on scale, mixed on profitability and not trivial on leverage.

Q3 FY2025 snapshot

In its fiscal Q3 2025 results, released in August, Amentum reported: ^[24]

Revenue of $3.6 billion, up about 2% year‑over‑year
Adjusted diluted EPS of $0.56, roughly 80% above the prior consensus estimate of $0.31
Adjusted EBITDA of $274 million, up 7% year‑over‑year
Free cash flow of around $100 million for the quarter
Net leverage reduced to about 3.5x

Those numbers helped management raise full‑year guidance and underscore the benefits of merger integration and portfolio pruning (including divestitures).

Margins, balance sheet and risk flags

Data compiled by GuruFocus and other analytics platforms paint a more nuanced picture: ^[25]

Trailing revenue is roughly $12.7 billion, with a three‑year revenue growth rate around 17–18%.
However, net margin is only about 0.4%, with EBITDA margins in the mid‑single digits, indicating that much of Amentum’s scale is not yet translating into high profitability.
Liquidity looks adequate, with a current and quick ratio near 1.6, but debt‑to‑equity stands around 1.0, reflecting meaningful leverage.
An Altman Z‑Score near 1.7 puts the firm in what credit models label the “distress” zone, signaling higher‑than‑average financial risk if conditions deteriorate.
On valuation metrics, P/E sits around 60x, while price‑to‑sales is under 0.5x and price‑to‑book around 1.3x, a combination some bulls cite as evidence of undervaluation relative to revenue and assets, but which also reflects low margins and capital intensity.

TipRanks’ write‑up of the UBS rating stresses that funded backlog has recently declined and growth projections for FY2026 look flat, limiting confidence in a near‑term multiple re‑rating despite Amentum’s long‑term contract base. ^[26]

Valuation tug‑of‑war: Citron’s $55 vs Street’s high‑$20s

With Wednesday’s spike to about $24.7, Amentum now trades: ^[27]

slightly above UBS’s $25 price target,
roughly 12–15% below the Street‑wide average target clustered in the high‑$20s,
and well below Citron’s aggressive $55 target, which implies the stock could more than double if its nuclear thesis proves right. ^[28]

Other perspectives muddy the waters further:

Simply Wall St argues that, even after a recent pullback (before today’s rally), AMTM might already be trading above its estimate of fair value, citing expensive earnings multiples and execution risk. ^[29]
Community and model‑driven valuations collected there span a very wide range (roughly low‑$20s to mid‑$80s per share), underscoring just how controversial the name is. ^[30]

UBS and JPMorgan emphasize valuation and growth visibility constraints, while Cantor Fitzgerald and Citron frame the stock as a leveraged play on a multi‑decade nuclear build‑out, especially if U.S. policy moves more aggressively toward nuclear‑powered baseload capacity. ^[31]

Key risks: government budgets, balance sheet and share overhang

Investors piling into AMTM after today’s move are also wrestling with a set of well‑flagged risks:

Government spending and program risk
Prior coverage from Barron’s and Investopedia noted that Amentum’s shares sold off earlier when management warned that the winding down of certain government programs could offset growth from new awards, weighing on fiscal 2025 expectations. ^[32]
Balance‑sheet leverage and distress indicators
With an Altman Z‑Score below 2 and net leverage still in the mid‑3x area, Amentum is more exposed than some peers if interest rates stay high or if contract timing and cash collection wobble. ^[33]
Backlog and growth visibility
UBS and TipRanks point to a recent dip in funded backlog and flat medium‑term growth forecasts, suggesting that, outside of marquee nuclear and defense wins, underlying momentum may not yet match the stock’s more speculative narratives. ^[34]
Potential share overhang
In its coverage note, UBS also flagged that Amentum has filed a prospectus enabling the potential sale of more than 90 million shares by existing stockholders. Amentum itself would not receive any proceeds, but would pay the registration costs – meaning additional supply could hit the market without adding cash to the balance sheet. ^[35]
Execution and management depth
Simply Wall St highlights that Amentum’s management team and board are relatively new in their current configuration, and that sustaining margins and integrating recent wins—from MQ‑9 to Sellafield—will require flawless execution. ^[36]

What to watch next

Q4 and full‑year 2025 earnings on November 25

Amentum has scheduled its fourth‑quarter and full‑fiscal‑year 2025 earnings call for November 25, 2025 at 8:30 a.m. EST, with results for the year ended October 3 due just before the call. ^[37]

Investors will be looking for:

Updated backlog and book‑to‑bill trends
Margin trajectory and any commentary on nuclear and unmanned systems profitability
Details on the ramp‑up of the MQ‑9 contract and early work under the Sellafield framework
Clarification on capital allocation, leverage targets and any use of secondary share capacity

Policy and macro catalysts

Beyond earnings, today’s nuclear‑driven rally has tethered AMTM tightly to:

U.S. nuclear policy, including potential DOE loan programs, reactor restart initiatives and new‑build capacity targets; ^[38]
Defense and intelligence budgets in the U.S. and UK, given Amentum’s heavy exposure to classified, mission‑critical work; ^[39]
Broader market sentiment toward nuclear and defense equities, where Amentum now trades alongside names like Constellation, BWX Technologies and Cameco in many nuclear‑themed baskets. ^[40]

Bottom line

November 19, 2025 will likely be remembered as Amentum’s “nuclear day” on Wall Street.

A double‑digit stock surge, Citron’s high‑profile endorsement and UBS’s more measured initiation have dragged AMTM squarely into the spotlight just days before a pivotal earnings release. The company’s deep entrenchment in U.S. nuclear infrastructure and defense, combined with recent MQ‑9 and Sellafield wins, offers a compelling long‑term story.

At the same time, thin margins, meaningful leverage, backlog questions and a potential share overhang mean that Wednesday’s enthusiasm comes with real risk attached. For now, the market is busy trying to decide whether Amentum is a once‑in‑a‑generation nuclear infrastructure play, or simply a good contractor that’s suddenly priced for perfection.

This article is for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should do their own research or consult a licensed financial professional before making investment decisions.

Is Amentum Holdings Inc AMTM Stock a Good Time to Buy Now?